NASDAQ:FLNA

Cassava Sciences Q1 2026 Earnings Results & Report

Cassava Sciences logo
$0.53 +0.05 (+11.15%)
As of 02:47 PM Eastern

Cassava Sciences reported Q1 2026 earnings on May 7, 2026. The company reported EPS of -$0.21.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Cassava Sciences EPS Results

Actual EPS
-$0.21
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Cassava Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cassava Sciences Q1 2026 Earnings FAQ

Cassava Sciences (NASDAQ:FLNA) reported earnings of -$0.21 per share for Q1 2026. The report was announced on Thursday, May 7, 2026.

Cassava Sciences Earnings Headlines

Cassava Sciences (NASDAQ:FLNA) Stock Sees Heavy Call Option Buying
Don’t delete this, read it today
Porter Stansberry has spent more than 30 years studying the economy and financial markets, and says he has never felt pressure like this. He believes the foundations beneath our way of life have cracked. One Nobel Prize winner has warned that the force behind it threatens to divide America. Stansberry points to rising living costs, deepening division and building anger as signs. His documentary, The Final Displacement, names the force and outlines what he believes you can do about it now.tc pixel
See More Cassava Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email.

About Cassava Sciences

Cassava Sciences (NASDAQ:FLNA) is a biotechnology company focused on developing treatments and diagnostic tools for Alzheimer’s disease. The company’s Nasdaq ticker is SAVA; FLNA does not correspond to Cassava Sciences.

Its research has included simufilam, an investigational oral drug candidate studied for Alzheimer’s, and SavaDX, a blood-based diagnostic program. These are products under development, not approved treatments or tests.

Founded in 1998 as Pain Therapeutics, the company adopted the Cassava Sciences name in 2018. It is headquartered in Austin, Texas, and has been led by founder and chief executive Remi Barbier.

View Cassava Sciences Profile